{"id":2705,"date":"2026-02-07T07:18:08","date_gmt":"2026-02-07T07:18:08","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/2705\/"},"modified":"2026-02-07T07:18:08","modified_gmt":"2026-02-07T07:18:08","slug":"jim-cramer-says-eli-lillys-constantly-taking-share-from-danish-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/2705\/","title":{"rendered":"Jim Cramer Says \u201cEli Lilly\u2019s Constantly Taking Share From Danish Novo Nordisk\u201d"},"content":{"rendered":"\n

Eli Lilly and Company (NYSE:LLY<\/a>) is one of the stocks Jim Cramer commented on<\/a>. Cramer noted that the company is \u201cconstantly taking share\u201d from its competition, as he remarked:<\/p>\n

We have the chief maker of the GLP-1s, Eli Lilly, soaring more than 10% as it rolls out trial after trial to see what these drugs can do beyond weight loss and diabetes, things like alcohol and tobacco addiction. They can make the ATF obsolete. Lilly\u2019s got a joint venture with NVIDIA where they\u2019re going\u2026 after hard-to-treat diseases. Hey, come on. With that kind of firepower, they\u2019ll develop a new line of forever, people. Lilly\u2019s gain is also arch rival Nova Nordisk\u2019s pain. It\u2019s not enough that President Trump wants to annex Greenland. Eli Lilly\u2019s constantly taking share from Danish Novo Nordisk.<\/p>\n

\"\" <\/p>\n

Photo by Adam Nowakowski<\/a> on Unsplash<\/a><\/p>\n

Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions. Hardman Johnston Global Equity Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2025 investor letter<\/a>:<\/p>\n

The top individual contributors to relative performance during the quarter were Standard Chartered PLC, Eli Lilly and Company (NYSE:LLY) and Hitachi, Ltd. Eli Lilly announced a deal with the U.S. administration that includes a three-year exemption from tariffs and the sale of GLP-1 therapies through government channels at discounted prices. Access to these channels significantly expands the addressable patient population and supports meaningful volume growth. Strong operating results and an upgraded 2025 outlook were driven by continued momentum from Mounjaro and Zepbound. Eli Lilly continues to gain share from Novo Nordisk across both diabetes and obesity markets, with prescription trends for both products remaining robust. Orforglipron (oral GLP-1) approval and commercial launch anticipated in 2026. This is likely the most watched commercial launch of all time with extremely high expectations.<\/p>\n

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 30 Stocks That Should Double in 3 Years<\/a> and

Insider Monkey<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer noted that the…\n","protected":false},"author":2,"featured_media":2706,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2960,2961,2964,272,2963,2962],"class_list":{"0":"post-2705","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-eli-lilly-and-company","9":"tag-jim-cramer","10":"tag-medicines-for-diabetes","11":"tag-novo-nordisk","12":"tag-president-trump","13":"tag-weight-loss-and-diabetes"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/2705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=2705"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/2705\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/2706"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=2705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=2705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=2705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}